ANDA 206840, held by Alvogen. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 206840 (Methylphenidate Hydrochloride), held by Alvogen, was first approved by FDA on Sep 15, 2016, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2016 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG ยท tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG ยท tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG ยท tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Oct 2, 2026 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Jun 3, 2024 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Sep 15, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters